More than $50 million in fines has been issued to drug giant Sanofi by France’s Antitrust Authority for what the regulator called a ‘smear campaign’ by the pharmaceutical company against generics drugs. Reports say the Authority found that Sanofi hampered competition by encouraging doctors and pharmacies to provide its brand name blood thinner drug Plavix instead of the generic form. Sanofi said it will appeal the fine. According to reports, Sanofi has looked to up profits since patent protection ended for two of its top-earning drugs, Plavix and blook pressure drug Avapro.
Full Content: Fox Business
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
House Passes ‘Take It Down Act,’ the First Major AI-Related Federal Regulation
Apr 29, 2025 by
CPI
Michigan Sues Express Scripts, Prime Therapeutics for Alleged Price-Fixing Scheme
Apr 29, 2025 by
CPI
Tech Rivals Testify as FTC Antitrust Trial Against Meta Enters Defining Phase
Apr 29, 2025 by
CPI
Spanish Judge Investigates Nationwide Blackout as Possible Cyber Threat
Apr 29, 2025 by
CPI
Trump Administration Pushes EU to Delay AI Regulations
Apr 29, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Mergers in Digital Markets
Apr 21, 2025 by
CPI
Catching a Killer? Six “Genetic Markers” to Assess Nascent Competitor Acquisitions
Apr 21, 2025 by
John Taladay & Christine Ryu-Naya
Digital Decoded: Is There More Scope for Digital Mergers In 2025?
Apr 21, 2025 by
Colin Raftery, Michele Davis, Sarah Jensen & Martin Dickson
AI In the Mix – An Ever-Evolving Approach to Jurisdiction Over Digital Mergers in Europe
Apr 21, 2025 by
Ingrid Vandenborre & Ketevan Zukakishvili
Antitrust Enforcement Errors Due to a Failure to Understand Organizational Capabilities and Dynamic Competition
Apr 21, 2025 by
Magdalena Kuyterink & David J. Teece